共 50 条
- [1] First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancersJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (02) : 441 - 448Landre, ThierryGuetz, Gaetan DesChouahnia, KaderTaleb, CherifaVergnenegre, AlainChouaid, Christos
- [2] PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancerJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (11)Yu, HuiChen, PingXia, LiangpingFu, ShaChen, ChenZhang, XuanyeHe, LinaZhang, BeiZhou, YixinHong, Shaodong
- [3] Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung CancerFRONTIERS IN ONCOLOGY, 2020, 10Zhai, XiaoyangJing, XuquanLi, JiTian, YaruXu, ShuhuiWang, MinZhu, Hui
- [4] Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1%.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Landre, ThierryGuetz, Gaetan DesChouahnia, KaderTaleb, CherifaVergnenegre, AlainChouaid, Christos
- [5] PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective StudyJCO PRECISION ONCOLOGY, 2023, 7Chen, MifenWang, ZhenghangLiu, ZiminDeng, TingWang, XiaodongChang, ZhiweiZhang, QiYang, WenleiLiu, NingJi, ZhiZhang, XiaotianWang, XichengPeng, ZhiLi, YiCao, YujuanJin, XuanLu, HongxiaQu, HuajunTang, YongXu, ChunleiFang, WeijiaZhang, HangyuYan, DongWang, LiLi, JiayiZhang, JingdongWang, QiweiXue, LiyingYin, FeiHan, GuangjieCheng, ZhiqiangLiu, QingJin, YongdongZhang, YinjieLi, LanxingCao, BaoshanYao, YanhongChen, ZhiyuZou, JianlingYing, JieerWei, QingTian, TiantianZhao, WeifengLi, LongmeiZhang, TongSong, FanghuaBa, Ya-erLi, NaGao, HuiJi, Yinghua
- [6] Clinical benefit of anti PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment in advanced non-small cell lung cancer: A meta-analysisANNALS OF ONCOLOGY, 2019, 30Landre, T.Des Guetz, G.Vergnenegre, A.Chouaid, C.
- [7] Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancerSUPPORTIVE CARE IN CANCER, 2022, 30 (02) : 1633 - 1641Miyawaki, TaichiNaito, TateakiYabe, MichitoshiKodama, HiroakiNishioka, NaoyaMiyawaki, ErikoMamesaya, NobuakiKobayashi, HarukiOmori, ShotaWakuda, KazushigeOno, AkiraKenmotsu, HirotsuguMurakami, HaruyasuMori, KeitaHarada, HideyukiTakahashi, KazuhisaTakahashi, Toshiaki
- [8] Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancerSupportive Care in Cancer, 2022, 30 : 1633 - 1641Taichi MiyawakiTateaki NaitoMichitoshi YabeHiroaki KodamaNaoya NishiokaEriko MiyawakiNobuaki MamesayaHaruki KobayashiShota OmoriKazushige WakudaAkira OnoHirotsugu KenmotsuHaruyasu MurakamiKeita MoriHideyuki HaradaKazuhisa TakahashiToshiaki Takahashi
- [9] Clinical impact of tumour burden on the efficacy of PD-1/PD-L1 inhibitors plus chemotherapy in non-small-cell lung cancerCANCER MEDICINE, 2023, 12 (02): : 1451 - 1460Miyawaki, TaichiKenmotsu, HirotsuguDoshita, KoseiKodama, HiroakiNishioka, NaoyaIida, YukoMiyawaki, ErikoMamesaya, NobuakiKobayashi, HarukiOmori, ShotaKo, RyoWakuda, KazushigeOno, AkiraNaito, TateakiMurakami, HaruyasuMori, KeitaHarada, HideyukiEndo, MasahiroTakahashi, KazuhisaTakahashi, Toshiaki
- [10] PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinomaEuropean Archives of Oto-Rhino-Laryngology, 2023, 280 : 1 - 9Dun-Chang MoJian-Feng HuangPeng-Hui LuoLong ChenBiao ZouHan-Lei Wang